View of Clinical Outcomes, Laboratory Safety, and Drug-Acquisition Cost Analysis of Generic versus Brand-Name Palbociclib in HR+/HER2− Metastatic Breast Cancer: A Real-World Ambispective Cohort Study from Iraq

Return to Article Details Clinical Outcomes, Laboratory Safety, and Drug-Acquisition Cost Analysis of Generic versus Brand-Name Palbociclib in HR+/HER2− Metastatic Breast Cancer: A Real-World Ambispective Cohort Study from Iraq Download Download PDF